John S Mcmurray

US Patent:

6923993, Aug 2, 2005

Filed:

Dec 12, 2001

Appl. No.:

10/020816

Inventors:

Nicholas D. Donato - San Marcos CA, US
Nicholas J. Donato - Sugarland TX, US
David C. Sample - Porter TX, US
Margot Perez - Houston TX, US
John S. McMurray - Houston TX, US
Robert A Newman - Sugarland TX, US

International Classification:

A61K035/78

US Classification:

424773, 424725

Abstract:

The present invention is directed to a process of isolating an extract from a (EO) plant by: preparing a sample of said plant comprising removal of the latex material; dissolving said sample with first solvent to form a solution; separating said solution into a liquid and a pulp fraction; and purifying said pulp fraction. The isolated EO extract induces apoptosis and inhibits growth of a cancerous cell. Thus, the present invention is also directed to a method for inducing apoptosis and growth inhibition of a cancerous cell by contacting the cell with an effective amount of the EO extract by the process of the invention. Preferably, the extract is administered both to the tumor directly and intravenously. The preferred lines of cancerous cells are melanoma, non-small cell lung cancer, prostate cancer, breast carcinoma, ovarian cancer, lymphoma and leukemia cells.

US Patent:

7099843, Aug 29, 2006

Filed:

Mar 14, 2002

Appl. No.:

10/096584

Inventors:

Henry James Cassidy - Arlington VA, US
David Kevin Horne - Arlington VA, US
Tyler Taile Yang - Potomac MD, US
John Patrick McMurray - McLean VA, US

Assignee:

Freddie Mac, The Federal Home Loan Mortgage Co. - McLean VA

International Classification:

G06F 17/60

US Classification:

705 38, 705 35, 705 36 R

Abstract:

The disclosed systems and methods for hedging risk of differential loss related to separate pools of loan investments use criteria established by the parties for hedging risk of differential loss rates. The system monitors indirect performance indicators for a Reference Pool and a Subject Pool of loans, compares the indicators, and calculates a payment due between the parties (if any) based on performance differences for the two pools and a payment formula. Any payment due is paid according to a pre-established payment cycle. The loan pools may be formed and adjusted based on various factors, such as to compensate for changes in one of the pools. The payment formula may also be adjusted to compensate for changes or differences in the loan pools. The system may hedge either party's credit loss related to the Subject Pool if its loans perform differently than the loans in the Reference Pool.

US Patent:

20070010428, Jan 11, 2007

Filed:

Sep 2, 2005

Appl. No.:

11/219530

Inventors:

John McMurray - Houston TX, US
Zhiyong Ren - Houston TX, US
David Coleman - Houston TX, US
Pijus Mandal - Houston TX, US
Xiaomin Chen - Houston TX, US
Warren Liao - Houston TX, US

International Classification:

A61K 38/08
A61K 38/06
A61K 38/05

US Classification:

514007000, 514017000, 514018000

Abstract:

Stat3 inhibitor compounds are disclosed, wherein the compounds are structural analogs of Ac-pTyr-Leu-Pro-Gln-Thr-NHand bind to the SH2 domain of Stat3 under physiological conditions to inhibit a cellular signaling activity of Stat3.

US Patent:

20120035114, Feb 9, 2012

Filed:

Apr 9, 2010

Appl. No.:

13/263815

Inventors:

John S. McMurray - Houston TX, US
Pijus K. Mandal - Houston TX, US
Warren S. Liao - Houston TX, US
Fredika Robertson - Houston TX, US
Xiaomin Chen - Houston TX, US
Zhiyong Ren - Houston TX, US

Assignee:

BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM - Austin TX

International Classification:

A61K 38/05
A61P 35/00
C07K 1/00
C07F 9/40

US Classification:

514 193, 540487, 514 2191, 548414, 548413, 530402

Abstract:

Compounds which inhibit the activity of signal transducer and activator of transcription 3 (STAT3) are provided together with methods of making and using the same. The compounds are designed to bind to the SH2 domain of STAT3, preventing STAT3 from binding to receptors for interleukin-6 family cytokines, growth factors such as the platelet-derived growth factor, the epidermal growth factor, vascular endothelial growth factor, and other signaling molecules such as leptin. Blocking these interactions prevents STAT3 from being phosphorylated on Tyr705, which is required for the dimerization of STAT3, translocation to the nucleus, binding to STAT3 response elements on promotors, and transcription of genes. In addition to these activities, binding to the SH2 domain of STAT3 breaks up pre-formed dimmers, thereby preventing the transcriptional activity of the inhibitor.

US Patent:

61774057, Jan 23, 2001

Filed:

Jul 22, 1992

Appl. No.:

7/918588

Inventors:

Kenji Nishioka - Houston TX
John S. McMurray - Houston TX
B. Montgomery Pettitt - Houston TX
Fahad Al-Obeidi - Amman, JO

International Classification:

A61K 3812
C07K 764

US Classification:

514 11

Abstract:

The useful cyclic peptides cyclo[Thr-Lys-Pro-Arg-Gly] and cyclo[Thr-Lys-Pro-Arg-Asp] are disclosed.